Atricure and baheal group establish partnership and china
distribution agreement
Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments for atrial fibrillation (afib) and left atrial appendage management, today announced it has partnered with baheal pharmaceutical group in china to distribute atricure’s surgical ablation devices. this new multi-year agreement establishes baheal as the exclusive distributor for atricure, and replaces the company’s previous distributor in china. “we are pleased to have formed this new partnership with baheal,” said michael carrel, atricure’s president and chief executive officer. “with baheal’s stellar reputation, their size and scale, combined with our market-leading devices, we are well positioned to establish a foundation for future growth in china.” atricure has been selling its surgical ablation devices in china for the past 14 years. during that time, several of china’s leading hospitals have adopted atricure devices, and in addition, the company expects to pursue new product approvals over the next several years to eventually bring its full portfolio of surgical ablation and left atrial appendage management devices into the market. “at baheal, we’re continuously looking for ways to grow and expand our business,” said fu gang, chairman of baheal pharmaceutical group. “we believe that there is vast opportunity to treat patients and the market remains underpenetrated, and we’re confident that together, we are well positioned to grow and help more patients in china affected by atrial fibrillation.” about atricure, inc. atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage (laa) exclusion system products are the most widely sold laa management devices worldwide, with more than 125,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure. about baheal group founded in 2005, baheal pharmaceutical group is a group enterprise devoted to the resource innovation and integration platform in the health industry. driven by the world’s cutting-edge intelligent information technologies, relying on its superb capability in health brand operation and management and building on its highly efficient industry resource integration abilities, the group has been digging deep in china’s medical and health care industry for more than a decade, providing optimized solutions for all links along the big health industry chain through the global brand ecosystem, intelligent application ecosystem, medical service ecosystem and investment ecosystem under its flag.
ATRC Ratings Summary
ATRC Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission